Seres Therapeutics (NASDAQ:MCRB) Shares Cross Below 50-Day Moving Average – Should You Sell?

Seres Therapeutics, Inc. (NASDAQ:MCRB) passed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $16.63 and traded as low as $14.50. Seres Therapeutics shares last traded at $15.05, with a volume of 38,823 shares changing hands.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of Seres Therapeutics in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Seres Therapeutics has a consensus rating of “Reduce” and a consensus price target of $14.33.

Seres Therapeutics Price Performance

The firm has a market capitalization of $136.20 million, a price-to-earnings ratio of -4.22 and a beta of 0.22. The business has a fifty day moving average price of $16.63 and a two-hundred day moving average price of $16.72.

Institutional Trading of Seres Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of MCRB. Bank of America Corp DE boosted its holdings in shares of Seres Therapeutics by 2,772.6% in the 3rd quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company’s stock valued at $103,000 after acquiring an additional 5,157 shares during the last quarter. XTX Topco Ltd acquired a new position in Seres Therapeutics during the second quarter valued at $249,000. Schonfeld Strategic Advisors LLC purchased a new stake in Seres Therapeutics in the third quarter valued at $557,000. Goldman Sachs Group Inc. boosted its holdings in Seres Therapeutics by 40.9% in the first quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 21,679 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in Seres Therapeutics during the 2nd quarter worth about $1,016,000. 59.34% of the stock is currently owned by institutional investors and hedge funds.

About Seres Therapeutics

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.